H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury
Lagerstedt, Linnéa (University of Geneva. Department of Human Protein Sciences)
Egea Guerrero, Juan José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Bustamante, Alejandro (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Montaner, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodríguez Rodríguez, Ana (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
El Rahal, Amir (Geneva University Hospitals (Suïssa))
Turck, Natacha (University of Geneva. Department of Human Protein Sciences)
Quintana, Manuel (Hospital Universitario La Paz (Madrid))
García Armengol, Roser (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Prica, Carmen Melinda (Hospital de Tortosa Verge de la Cinta)
Andereggen, Elisabeth (Geneva University Hospitals (Suïssa))
Rinaldi, Lara (Geneva University Hospitals (Suïssa))
Sarrafzadeh, Asita (Heidelberg University Hospital (Alemanya))
Schaller, Karl (Geneva University Hospitals (Suïssa))
Sanchez, Jean-Charles (University of Geneva. Department of Human Protein Sciences)

Data:	2017
Resum:	The majority of patients with mild traumatic brain injury (mTBI) will have normal Glasgow coma scale (GCS) of 15. Furthermore, only 5%±8% of them will be CT-positive for an mTBI. Having a useful biomarker would help clinicians evaluate a patient's risk of developing intracranial lesions. The S100B protein is currently the most studied and promising biomarker for this purpose. Heart fatty-acid binding protein (H-FABP) has been highlighted in brain injury models and investigated as a biomarker for stroke and severe TBI, for example. Here, we evaluate the performances of S100B and H-FABP for differentiating between CT-positive and CT-negative patients. A total of 261 patients with a GCS score of 15 and at least one clinical symptom of mTBI were recruited at three different European sites. Blood samples from 172 of them were collected 6 h after trauma. Patients underwent a CT scan and were dichotomised into CT-positive and CT-negative groups for statistical analyses. HFABP and S100B levels were measured using commercial kits, and their capacities to detect all CT-positive scans were evaluated, with sensitivity set to 100%. For patients recruited 6 h after trauma, the CT-positive group demonstrated significantly higher levels of both H-FABP (p = 0. 004) and S100B (p = 0. 003) than the CT-negative group. At 100% sensitivity, specificity reached 6% (95% CI 2. 8±10. 7) for S100B and 29% (95% CI 21. 4± 37. 1) for H-FABP. Similar results were obtained when including all the patients recruited, i. e. hospital arrival within 24 h of trauma onset. H-FABP out-performed S100B and thus seems to be an interesting protein for detecting all CT-positive mTBI patients with a GCS score of 15 and at least one clinical symptom.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	PloS one, Vol. 12 Núm. 4 (2017) , p. 1-11, ISSN 1932-6203

DOI: 10.1371/journal.pone.0175572
PMID: 28419114

11 p, 899.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats